The way of cholesterol in atherogenesis: from the main enemy to complex biomarkers

Anastasia V. Poznyak; Victoria A. Khotina; Mikhail A. Popov; Alexander D. Zhuravlev; Vasily N. Sukhorukov; Alexander N. Orekhov

doi:10.25163/angiotherapy.719348

Angiogenesis, Inflammation & Therapeutics | Online ISSN 2207-872X

REVIEWS (Open Access)

The way of cholesterol in atherogenesis: from the main enemy to complex biomarkers

Anastasia V. Poznyak ^1*, Victoria A. Khotina², Mikhail A. Popov ³, Alexander D. Zhuravlev ², Vasily N. Sukhorukov ², Alexander N. Orekhov ^2*

+ Author Affiliations

Journal of Angiotherapy 7 (1) 1-7 https://doi.org/10.25163/angiotherapy.719348

Submitted: 19 September 2023 Revised: 19 October 2023 Published: 22 October 2023

Abstract

Since the advent of the cholesterol hypothesis of atherosclerosis, cholesterol has been perceived by the world community as a great evil. However, normally cholesterol is an important component of the plasma membrane, as well as a participant in the signaling of bile acids, steroid hormones and vitamin D synthesis, and its deficiency has negative consequences. There is a much wider understanding of the negative effects of excess cholesterol. The pathogenesis of atherosclerosis, and hence all its negative consequences, such as myocardial infarction, Peripheral artery disease, stroke, etc., is inextricably linked with cholesterol. However, it is no longer entirely correct to perceive cholesterol as an unambiguous evil. So, for example, the indicator "total cholesterol" does not have the clinical significance that has been attributed to it for decades. Today we have a challenge to measure cholesterol and assess its pathogenicity. In this review, we collected data on current approaches to measuring cholesterol in the context of its relationship with atherosclerosis.

Keywords: atherosclerosis; CVD; cholesterol; lipid; LDL

References

Adam CA, ?alaru DL, Prisacariu C, Marcu DTM, Sascau RA, Statescu C. Novel Biomarkers of Atherosclerotic Vascular Disease-Latest Insights in the Research Field. Int J Mol Sci. 2022 Apr 30;23(9):4998. doi: 10.3390/ijms23094998. PMID: 35563387; PMCID: PMC9103799.

Aggarwal DJ, Kathariya MG, Verma DPK. LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker. Indian Heart J. 2021 Sep-Oct;73(5):544-548. doi: 10.1016/j.ihj.2021.07.013. Epub 2021 Jul 31. PMID: 34627566; PMCID: PMC8514398.

Alghazeer R, Burwaiss AA, Howell NK, Alansari WS, Shamlan G, Eskandrani AA. Determining the Cytotoxicity of Oxidized Lipids in Cultured Caco-2 Cells Using Bioimaging Techniques. Molecules. 2020 Apr 7;25(7):1693. doi: 10.3390/molecules25071693. PMID: 32272768; PMCID: PMC7180719.

Assadi SN. What are the effects of psychological stress and physical work on blood lipid profiles? Medicine (Baltimore). 2017 May;96(18):e6816. doi: 10.1097/MD.0000000000006816. PMID: 28471984; PMCID: PMC5419930.

Barona J, Fernandez ML. Dietary cholesterol affects plasma lipid levels, the intravascular processing of lipoproteins and reverse cholesterol transport without increasing the risk for heart disease. Nutrients. 2012 Aug;4(8):1015-25. doi: 10.3390/nu4081015. Epub 2012 Aug 17. PMID: 23016129; PMCID: PMC3448084.

Bartlomiejczyk, M.A., Penson, P. & Banach, M. Worldwide Dyslipidemia Guidelines. Curr Cardiovasc Risk Rep 13, 2 (2019). https://doi.org/10.1007/s12170-019-0597-x

Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, De Leon J, Glass AD, Reiss AB. Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites. 2021 Oct 8;11(10):690. doi: 10.3390/metabo11100690. PMID: 34677405; PMCID: PMC8540246.

Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000 Jul 4;102(1):21-7. doi: 10.1161/01.cir.102.1.21. PMID: 10880410.

Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA; National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol. 2008 Aug;2(4):267-73. doi: 10.1016/j.jacl.2008.06.013. Epub 2008 Jun 28. PMID: 21291742.

Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F. Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp Gerontol. 2009 Mar;44(3):136-60. doi: 10.1016/j.exger.2008.11.003. Epub 2008 Nov 17. PMID: 19041386; PMCID: PMC2730542.

Calling S, Johansson SE, Wolff M, Sundquist J, Sundquist K. Total cholesterol/HDL-C ratio versus non-HDL-C as predictors for ischemic heart disease: a 17-year follow-up study of women in southern Sweden. BMC Cardiovasc Disord. 2021 Apr 5;21(1):163. doi: 10.1186/s12872-021-01971-1. PMID: 33820540; PMCID: PMC8020530.

Chen L, Zhao ZW, Zeng PH, Zhou YJ, Yin WJ. Molecular mechanisms for ABCA1-mediated cholesterol efflux. Cell Cycle. 2022 Jun;21(11):1121-1139. doi: 10.1080/15384101.2022.2042777. Epub 2022 Feb 22. PMID: 35192423; PMCID: PMC9103275.

Cho KH, Park HJ, Kim JR. Decrease in Serum HDL-C Level Is Associated with Elevation of Blood Pressure: Correlation Analysis from the Korean National Health and Nutrition Examination Survey 2017. Int J Environ Res Public Health. 2020 Feb 9;17(3):1101. doi: 10.3390/ijerph17031101. PMID: 32050502; PMCID: PMC7036966.

Chung S, Sawyer JK, Gebre AK, Maeda N, Parks JS. Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation. 2011 Oct 11;124(15):1663-72. doi: 10.1161/CIRCULATIONAHA.111.025445. Epub 2011 Sep 19. PMID: 21931081; PMCID: PMC3202242.

Cockcroft S. Mammalian lipids: structure, synthesis and function. Essays Biochem. 2021 Nov 2;65(5):813-845. doi: 10.1042/EBC20200067. PMID: 34415021; PMCID: PMC8578989.

El-Hajjar L, Hindieh J, Andraos R, El-Sabban M, Daher J. Myeloperoxidase-Oxidized LDL Activates Human Aortic Endothelial Cells through the LOX-1 Scavenger Receptor. Int J Mol Sci. 2022 Mar 4;23(5):2837. doi: 10.3390/ijms23052837. PMID: 35269979; PMCID: PMC8910860.

Feingold KR. Cholesterol Lowering Drugs. [Updated 2021 Mar 30]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395573/

Fernandez C, Sandin M, Sampaio JL, Almgren P, Narkiewicz K, Hoffmann M, Hedner T, Wahlstrand B, Simons K, Shevchenko A, James P, Melander O. Plasma lipid composition and risk of developing cardiovascular disease. PLoS One. 2013 Aug 15;8(8):e71846. doi: 10.1371/journal.pone.0071846. PMID: 23967253; PMCID: PMC3744469.

Ganjali S, Watts GF, Banach M, Reiner Ž, Nachtigal P, Sahebkar A. The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. Curr Med Chem. 2021;28(29):6066-6081. doi: 10.2174/0929867328666210208182326. PMID: 33563147.

Glomset JA, Norum KR, Nichols AV, King WC, Mitchell CD, Applegate KR, Gong EL, Gjone E. Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: effects of dietary manipulation. Scand J Clin Lab Invest Suppl. 1975;142:3-30. PMID: 169566.

Guo LL, Chen YQ, Lin QZ, Tian F, Xiang QY, Zhu LY, Xu J, Wen T, Liu L. Non-HDL-C Is More Stable Than LDL-C in Assessing the Percent Attainment of Non-fasting Lipid for Coronary Heart Disease Patients. Front Cardiovasc Med. 2021 Apr 1;8:649181. doi: 10.3389/fcvm.2021.649181. PMID: 33869310; PMCID: PMC8049565.

Hajar R. Risk Factors for Coronary Artery Disease: Historical Perspectives. Heart Views. 2017 Jul-Sep;18(3):109-114. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_106_17. PMID: 29184622; PMCID: PMC5686931.

Hill MF, Bordoni B. Hyperlipidemia. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559182/

Hong LZ, Xue Q, Shao H. Inflammatory Markers Related to Innate and Adaptive Immunity in Atherosclerosis: Implications for Disease Prediction and Prospective Therapeutics. J Inflamm Res. 2021 Feb 16;14:379-392. doi: 10.2147/JIR.S294809. PMID: 33628042; PMCID: PMC7897977.

Jacobson TA. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc. 2011 Aug;86(8):762-80. doi: 10.4065/mcp.2011.0128. PMID: 21803958; PMCID: PMC3146376.

Jung HW, Hong SP, Kim KS. Comparison of apolipoprotein B/A1 ratio, TC/HDL-C, and lipoprotein (a) for predicting outcomes after PCI. PLoS One. 2021 Jul 13;16(7):e0254677. doi: 10.1371/journal.pone.0254677. PMID: 34255802; PMCID: PMC8277048.

Karjalainen JJ, Kiviniemi AM, Hautala AJ, Piira OP, Lepojärvi ES, Perkiömäki JS, Junttila MJ, Huikuri HV, Tulppo MP. Effects of physical activity and exercise training on cardiovascular risk in coronary artery disease patients with and without type 2 diabetes. Diabetes Care. 2015 Apr;38(4):706-15. doi: 10.2337/dc14-2216. Epub 2015 Jan 15. PMID: 25592198.

Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011 Jan 13;364(2):127-35. doi: 10.1056/NEJMoa1001689. PMID: 21226578; PMCID: PMC3030449.

Kjeldsen EW, Nordestgaard LT, Frikke-Schmidt R. HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review. Int J Mol Sci. 2021 Apr 27;22(9):4547. doi: 10.3390/ijms22094547. PMID: 33925284; PMCID: PMC8123633.

Kronenberg F. HDL in CKD-The Devil Is in the Detail. J Am Soc Nephrol. 2018 May;29(5):1356-1371. doi: 10.1681/ASN.2017070798. Epub 2018 Feb 22. PMID: 29472417; PMCID: PMC5967756.

Lande. K.E. and Sperry, W.M. (1936) Human Atherosclerosis in Relation to the Cholesterol Content of the Blood Serum. Archives of Pathology, 22, 301-312.

Lee YT, Laxton V, Lin HY, Chan YWF, Fitzgerald-Smith S, To TLO, Yan BP, Liu T, Tse G. Animal models of atherosclerosis. Biomed Rep. 2017 Mar;6(3):259-266. doi: 10.3892/br.2017.843. Epub 2017 Jan 17. PMID: 28451383; PMCID: PMC5403338.

Lim Y, Yoo S, Lee SA, Chin SO, Heo D, Moon JC, Moon S, Boo K, Kim ST, Seo HM, Jwa H, Koh G. Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes. Endocrinol Metab (Seoul). 2015 Jun;30(2):208-15. doi: 10.3803/EnM.2015.30.2.208. PMID: 26194080; PMCID: PMC4508266.

Linton MRF, Yancey PG, Davies SS, et al. The Role of Lipids and Lipoproteins in Atherosclerosis. [Updated 2019 Jan 3]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK343489/

Mahdy Ali K, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol. 2012 Nov;167(6):1177-94. doi: 10.1111/j.1476-5381.2012.02081.x. PMID: 22725625; PMCID: PMC3504986.

Makover ME, Shapiro MD, Toth PP. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness. Am J Prev Cardiol. 2022 Aug 6;12:100371. doi: 10.1016/j.ajpc.2022.100371. PMID: 36124049; PMCID: PMC9482082.

Martin SS, Qasim AN, Mehta NN, Wolfe M, Terembula K, Schwartz S, Iqbal N, Schutta M, Bagheri R, Reilly MP. Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. Diabetes. 2009 Aug;58(8):1887-92. doi: 10.2337/db08-1794. Epub 2009 Jun 2. PMID: 19491209; PMCID: PMC2712798.

Masana L, Zamora A, Plana N, Comas-Cufí M, Garcia-Gil M, Martí-Lluch R, Ponjoan A, Alves-Cabratosa L, Elosua R, Marrugat J, Dégano IR, Ramos R. Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. J Clin Med. 2019 Jul 23;8(7):1080. doi: 10.3390/jcm8071080. PMID: 31340450; PMCID: PMC6678686.

Mathews SC, Mallidi J, Kulkarni K, Toth PP, Jones SR. Achieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based data. PLoS One. 2012;7(3):e33692. doi: 10.1371/journal.pone.0033692. Epub 2012 Mar 29. PMID: 22479428; PMCID: PMC3315574.

Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA. 2018 Apr 17;319(15):1566-1579. doi: 10.1001/jama.2018.2525. Erratum in: JAMA. 2018 Oct 2;320(13):1387. PMID: 29677301; PMCID: PMC5933331.

Nigam PK. Serum Lipid Profile: Fasting or Non-fasting? Indian J Clin Biochem. 2011 Jan;26(1):96-7. doi: 10.1007/s12291-010-0095-x. Epub 2010 Dec 29. PMID: 22211025; PMCID: PMC3068759.

Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013 Mar 18;5(3):928-48. doi: 10.3390/nu5030928. PMID: 23507795; PMCID: PMC3705327.

Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30. Erratum in: Stroke. 2019 Dec;50(12):e440-e441. PMID: 31662037.

Pradhan A, Bhandari M, Vishwakarma P, Sethi R. Triglycerides and Cardiovascular Outcomes-Can We REDUCE-IT ? Int J Angiol. 2020 Mar;29(1):2-11. doi: 10.1055/s-0040-1701639. Epub 2020 Feb 25. PMID: 32132810; PMCID: PMC7054063.

Prasad Tharu B, Tsokos CP. A Statistical Study of Serum Cholesterol Level by Gender and Race. J Res Health Sci. 2017 Jul 25;17(3):386. PMCID: PMC7189954.

Qi Q, Qi L. Lipoprotein(a) and cardiovascular disease in diabetic patients. Clin Lipidol. 2012 Aug;7(4):397-407. doi: 10.2217/clp.12.46. PMID: 23136583; PMCID: PMC3488449.

Quispe R, Elshazly MB, Zhao D, Toth PP, Puri R, Virani SS, Blumenthal RS, Martin SS, Jones SR, Michos ED. Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. Eur J Prev Cardiol. 2020 Oct;27(15):1597-1605. doi: 10.1177/2047487319862401. Epub 2019 Jul 10. PMID: 31291776; PMCID: PMC6952589.

Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009 Apr;50 Suppl(Suppl):S189-94. doi: 10.1194/jlr.R800088-JLR200. Epub 2008 Dec 8. PMID: 19064999; PMCID: PMC2674717.

Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012 Apr 17;125(15):1905-19. doi: 10.1161/CIRCULATIONAHA.111.066589. PMID: 22508840; PMCID: PMC4159082.

Sacks FM, Jensen MK. From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):487-499. doi: 10.1161/ATVBAHA.117.307025. Epub 2018 Jan 25. PMID: 29371248; PMCID: PMC5823773.

Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012 Feb;14(1):1-10. doi: 10.1007/s11883-011-0219-7. PMID: 22102062; PMCID: PMC3697085.

Sandesara PB, Virani SS, Fazio S, Shapiro MD. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocr Rev. 2019 Apr 1;40(2):537-557. doi: 10.1210/er.2018-00184. PMID: 30312399; PMCID: PMC6416708.

Shea S, Stein JH, Jorgensen NW, McClelland RL, Tascau L, Shrager S, Heinecke JW, Yvan-Charvet L, Tall AR. Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque. Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):89-96. doi: 10.1161/ATVBAHA.118.311366. PMID: 30580560; PMCID: PMC6310062.

Si S, Hou L, Chen X, Li W, Liu X, Liu C, Li Y, Yuan T, Li J, Wang B, Li H, Xue F. Exploring the Causal Roles of Circulating Remnant Lipid Profile on Cardiovascular and Cerebrovascular Diseases: Mendelian Randomization Study. J Epidemiol. 2022 May 5;32(5):205-214. doi: 10.2188/jea.JE20200305. Epub 2021 Jul 10. PMID: 33441507; PMCID: PMC8979919.

Solberg LA, Strong JP. Risk factors and atherosclerotic lesions. A review of autopsy studies. Arteriosclerosis. 1983 May-Jun;3(3):187-98. doi: 10.1161/01.atv.3.3.187. PMID: 6342587.

Stone NJ, Grundy SM. The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. Prog Cardiovasc Dis. 2019 Sep-Oct;62(5):375-383. doi: 10.1016/j.pcad.2019.11.005. Epub 2019 Nov 13. PMID: 31733217.

Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010 Nov;5(6):463-6. doi: 10.1097/COH.0b013e32833ed177. PMID: 20978388; PMCID: PMC3078627.

Sweeney T, Quispe R, Das T, Juraschek SP, Martin SS, Michos ED. The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review. Expert Rev Precis Med Drug Dev. 2021;6(4):247-258. doi: 10.1080/23808993.2021.1930531. Epub 2021 May 26. PMID: 34423130; PMCID: PMC8372373.

Temel RE, Brown JM. A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion. Trends Pharmacol Sci. 2015 Jul;36(7):440-51. doi: 10.1016/j.tips.2015.04.002. Epub 2015 Apr 27. PMID: 25930707; PMCID: PMC4485953.

Temel RE, Brown JM. Biliary and nonbiliary contributions to reverse cholesterol transport. Curr Opin Lipidol. 2012 Apr;23(2):85-90. doi: 10.1097/MOL.0b013e3283508c21. PMID: 22262055; PMCID: PMC3711548.

Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids. 2015;2015:971453. doi: 10.1155/2015/971453. Epub 2015 Apr 8. PMID: 25949827; PMCID: PMC4407625.

Viigimaa M, Abina J, Zemtsovskaya G, Tikhaze A, Konovalova G, Kumskova E, Lankin V. Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis. Blood Press. 2010 Jun;19(3):164-8. doi: 10.3109/08037051.2010.484158. PMID: 20429692.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468. PMID: 34458905.

Wilkins JT, Li RC, Sniderman A, Chan C, Lloyd-Jones DM. Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study. J Am Coll Cardiol. 2016 Jan 19;67(2):193-201. doi: 10.1016/j.jacc.2015.10.055. PMID: 26791067; PMCID: PMC6613392.

Yanai H, Adachi H, Hakoshima M, Katsuyama H. Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk. Int J Mol Sci. 2022 Nov 4;23(21):13499. doi: 10.3390/ijms232113499. PMID: 36362288; PMCID: PMC9657259.

Yazdanyar A, Yeang C, Jiang XC. Role of phospholipid transfer protein in high-density lipoprotein- mediated reverse cholesterol transport. Curr Atheroscler Rep. 2011 Jun;13(3):242-8. doi: 10.1007/s11883-011-0172-5. PMID: 21365262; PMCID: PMC3085729.

Zaric BL, Radovanovic JN, Gluvic Z, Stewart AJ, Essack M, Motwalli O, Gojobori T, Isenovic ER. Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes. Front Immunol. 2020 Sep 28;11:551758. doi: 10.3389/fimmu.2020.551758. PMID: 33117340; PMCID: PMC7549398.

PDF
Abstract
Export Citation

View Dimensions

View Plumx

View Altmetric

Save

0
Citation

560
View

Share